文献速递流行病学与生物统计临床试验与 GCP

系列:实用性试验与真实世界证据:第3篇 患者选择挑战及后果

Series: Pragmatic trials and real world evidence: Paper 3. Patient selection challenges and consequences.
PubMed 文献 · J Clin Epidemiol · 2017-05-11

本文讨论在常规诊疗环境中开展试验时识别、入组和保留参与者的挑战。实用性试验应考虑所有常规临床实践中可能适合治疗的患者为合格对象,通过纳入选定站点内所有患者而不进一步筛选来保证泛化性。选择仍会发生,低入组率和失访可引入选择偏倚并危及有效性和泛化性,但若试验对医患负担最小且最大化遵循常规实践,参与率可能较高且失访不会成为实用性问题。

要点

  • 所有常规临床实践中可能适合治疗的患者均应考虑为实用性试验的合格对象。
  • 为保证泛化性,招募样本的治疗效应修饰因子分布应与目标人群相似。
  • 低入组和失访可引入选择偏倚并危及有效性和泛化性。

核心结论

  • 在常规诊疗环境中开展试验时,应通过纳入选定站点内所有患者而不进一步筛选来保证泛化性,但选择仍会发生,低入组和失访可引入选择偏倚并危及有效性和泛化性。

研究设计与样本

  • 本文为方法学系列文章,讨论在常规诊疗环境中开展试验时识别、入组和保留参与者的挑战及后果。
  • 原文未报告具体研究设计、样本量或数据来源。

主要发现

  • 所有常规临床实践中可能适合治疗的患者均应考虑为实用性试验的合格对象。
  • 为保证泛化性,招募样本的治疗效应修饰因子分布应与目标人群相似。
  • 若预期亚组间存在相关异质性,可考虑在异质性试验中增加该亚组患者的相对比例(过采样)或计划在该亚组中开展单独试验。
  • 低入组和失访可引入选择偏倚并危及有效性和泛化性。
  • 若试验对医生和患者负担最小且最大化遵循常规临床实践,参与率可能较高且失访不会成为实用性试验的特有问题。

关键数值与推荐

  • 原文未报告具体数值标准或推荐条款。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This paper addresses challenges of identifying, enrolling, and retaining participants in a trial conducted within a routine care setting. All patients who are potential candidates for the treatments in routine clinical practice should be considered eligible for a pragmatic trial. To ensure generalizability, the recruited sample should have a similar distribution of the treatment effect modifiers as the target population. In practice, this can be best achieved by including-within the selected sites-all patients without further selection. If relevant heterogeneity between subgroups is expected, increasing the relative proportion of the subgroup of patients in the heterogeneous trial could be considered (oversampling) or a separate trial in this subgroup can be planned. Selection will nevertheless occur. Low enrollment and loss to follow-up can introduce selection and can jeopardize validity as well as generalizability. Pragmatic trials are conducted in clinical practice rather than in a dedicated research setting, which could reduce recruitment rates. However, if a trial poses a minimal burden to the physician and the patient and routine clinical practice is maximally adhered to, the participation rate may be high and loss to follow-up will not be a specific problem for pragmatic trials.

来源:J Clin Epidemiol,查看原文。版权归原作者所有。

引用

  1. Oude Rengerink K, Kalkman S, Collier S, et al. Series: Pragmatic trials and real world evidence: Paper 3. Patient selection challenges and consequences. J Clin Epidemiol. 2017. PMID: 28502808. doi:10.1016/j.jclinepi.2016.12.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。